Cambridge Healthtech Institute’s 5th Annual

Target Identification & Phenotypic Screening

Leveraging Functional Genomics, Cellular Assays and Computational Tools

June 19-20, 2019


Identifying novel, druggable targets for therapeutic intervention or probing existing drug targets for new therapeutic indications is a crucial part of the early discovery process. Target-based and phenotypic screening are most commonly used approaches for finding and validating drug targets. How well do these approaches work? What new technologies are being developed? How do you evaluate and decide on which technique or assay to use? Are there ways to screen “hard-to-find” targets? Cambridge Healthtech Institute’s conference on Target Identification & Phenotypic Screening brings together experts from pharma/biotech and academia to address some of these questions and more. It provides a unique networking opportunity for people to interact, share ideas and discuss new strategies and technologies helping target discovery.

USE OF NEW SCREENING PLATFORMS FOR FINDING NOVEL TARGETS

Genome Editing in Stem Cells for Generating Disease Relevant Cellular Models in Drug Discovery

Filip Roudnicky, PhD, Senior Scientist, pRED, F. Hoffmann-La Roche Ltd

Establishment of High-Throughput Screening Platforms for Identification of Protein Degraders 

Davide Gianni, PhD, Associate Director, Discovery Sciences, AstraZeneca

Challenges and Opportunities in 3D High-Throughput Screening

Ying Qian, PhD, Associate Principal Scientist, Screening & Compound Profiling, Merck Research Laboratories

IN VIVO TARGET SCREENING FOR EXPLORING DISEASE BIOLOGY AND MOA STUDIES

Application of CRISPR Technology to In vivo Models of Cancer Immunotherapy

John Doench, PhD, Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

TECHNOLOGY PANEL: Do We Have the Right Tools to Find Drug Targets That Are Difficult to Identify and Validate?

This panel will bring together speakers and 3-5 technical experts from leading technology and service companies to discuss improvements and limitations in assays, platforms, and data analysis tools available for target discovery and validation.

Moderator: John Doench, PhD, Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

EXPLOITING VARIOUS ASSAYS AND PLATFORMS FOR PHENOTYPIC SCREENING

Hit Triage and Validation for Phenotypic Screening: Considerations and Strategies

Fabien Vincent, PhD, Associate Research Fellow, Hit Discovery and Lead Profiling Group, Pfizer

Frequent Hitters in Phenotypic Screens and Where to Find Them

Yuan Wang, PhD, Investigator III, Data Science, Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research

CASE STUDY: Phenotypic Screen for Alzheimer's Disease: From Compounds to Novel Pathways

Nava Krishnan, PhD, Senior Scientist, Molecular Screening and Characterization, Abbvie Inc.

CASE STUDY: Identification of the Molecular Target of MTBL0036, a Promising Anti-NASH and Anti-fibrotic Drug Candidate Selected by a Phenotypic Approach

Gabriel Baverel, DVM, PhD, President, Founder and CSO, Metabolys

EXPLORING USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TOOLS

Using Machine Learning Methods to Prioritize Drug Combinations Selected Using RNAi-based Phenotypic Screening

Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, The University of Michigan

Approaches to Identify and Validate Targets Through Integrative Analytical Approaches for Different Indications 

Deepak K Rajpal, Senior Scientific Director, GSK R&D
Johannes M Freudenberg, Senior Scientific Investigator, GSK R&D


For more details on the conference, please contact:
Tanuja Koppal, PhD
Conference Producer
Cambridge Healthtech Institute
Email: tkoppal@healthtech.com

For partnering and sponsorship information, please contact:


Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com